Tebotelimab Is Safe and Effective Across Multiple Cancer Types

Article navigation

Research Watch| January 12 2024

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2024) 14 (1): OF4.

Abstract

The PD-1 × LAG-3 bispecific molecule tebotelimab is safe as a monotherapy and in combination with margetuximab.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.